CASTEL SAN PIETRO, Switzerland, October 05, 2026 – Medacta Group SA ("Medacta" SIX:MOVE) today announces the appointment of Riccardo Fava as Group VP Investor Relations, Sustainability & Media Relations, effective October 1, 2026, reporting directly to CEO Francesco Siccardi.
Medacta Strengthens its Capital Markets and Communications Leadership with the Appointment of Riccardo Fava as New Group VP Investor Relations, Sustainability & Media Relations
2 min read Premium comments
appointmentMedacta Group SARiccardo FavaGroup VP Investor Relations, Sustainability & Media Relations
In his new role, Riccardo will oversee Medacta's relationships with investors, analysts and the media, as well as the Group's sustainability strategy and reporting. Bringing these areas together under a single leadership is intended to give Medacta a consistent and coordinated voice towards the international financial community, the media and its wider stakeholders as the Group continues to grow.
Riccardo brings more than 20 years of experience across the medtech and financial sectors. From 2011 he served as Corporate Vice President, Communication, ESG & Investor Relations at Diasorin, where he led the company's engagement with the global investment community, its corporate communication and its sustainability agenda.
"Riccardo combines deep knowledge of the medtech industry with long-standing experience in capital markets and sustainability," said Francesco Siccardi, CEO of Medacta. "As we expand our global footprint, particularly in the United States, clear and consistent communication with investors and stakeholders is more important than ever. I am delighted to welcome him to our team."
Riccardo holds a degree in Economics summa cum laude from the University of Turin and is a qualified Chartered Accountant. He has further complemented his education with postgraduate and executive programs in artificial intelligence, project management, corporate communication and digital marketing.
CONTACT
Riccardo Fava
Group VP Investor Relations, Sustainability & Media Relations
ABOUT MEDACTA GROUP SA Medacta Group SA (“Medacta”, SIX: MOVE) is a global key player specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgery. Established in 1999 in Switzerland, Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Through close collaboration with expert surgeons globally, continuous investments in R&D, and the adoption of cutting-edge technologies, Medacta’s innovation prioritizes minimally invasive surgery and personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 70 countries. Follow us on Medacta.com, Medacta TV, YouTube, LinkedIn and X
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Medacta Group SA appointed Riccardo Fava as Group VP Investor Relations, Sustainability & Media Relations, effective October 1, 2026. This strategic consolidation aims to ensure consistent, coordinated communication with the international financial community and stakeholders as Medacta expands its global footprint, particularly in the United States. Fava's extensive experience in medtech and capital markets will strengthen Medacta's engagement and support its growth trajectory.
- The unified leadership role signals Medacta's commitment to streamlined external messaging, crucial for capital market confidence during global expansion.
- This move enhances Medacta's strategic positioning by integrating investor relations, sustainability, and media under one experienced leader to support market penetration.
PhD Lens: Clinical and outcomes impact
Medacta Group SA announced a new executive appointment, not clinical data. The company specializes in innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta emphasizes minimally invasive surgery and personalized solutions, collaborating with expert surgeons and investing in R&D. Its M.O.R.E. Institute supports medical education, reflecting a commitment to advancing surgical practices and patient well-being.
- Medacta's core focus is on developing personalized and sustainable solutions across joint, sports medicine, and spine indications.
- The company prioritizes minimally invasive surgical techniques and continuous R&D, supported by surgeon collaboration and educational initiatives.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.